Ensitrelvir in mild to moderate Covid-19

In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, investigators evaluated the efficacy and safety of ensitrelvir in 1,821 patients with mild-to-moderate Covid-19. Patients were randomized to receive ensitrelvir 125 mg once daily (375 mg on day 1), ensitrelvir 250 mg once daily (750 mg on day 1) or placebo for 5 days. The primary endpoint was the duration of resolution of the five main symptoms of infection. Ensitrelvir 125 mg, initiated within 72 hours of the onset of the first signs of illness, reduced the duration of symptoms by around 1 day, compared with placebo.